ClinicalTrials.gg
CompletedNCT04380701Updated Jul 12, 2024Results posted

A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults

A Phase 1/2 interventional study of BNT162a1 and BNT162b1 in Infections, Respiratory, Virus Diseases and Infection Viral, sponsored by BioNTech SE. Completed at 5 sites in Germany. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-12.

Primary conditionCOVID-19Registry: Respiratory Tract InfectionsReclassifiedWhy we changed it
Registry
Respiratory Tract Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
COVID-19
Why
  1. The study's listed conditions name COVID-19, a narrower term within Respiratory Tract Infections.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by BioNTech SE · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
512
Allocation
Non-randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing BNT162 Vaccine in COVID-19 — 4 open to participants now, 6 under way, 1 of them phase 3. BNT162 Vaccine · COVID-19.

Enrollment
31st of 54
512 · median 575
Started
2020
with 4 others
Phase 1/2
3 of 54
none open now
Registered
2nd of 54
by date
Lead sponsor
20 of 54
BioNTech SE

Among the 54 studies testing BNT162 Vaccine in COVID-19, this one is the 31st largest by enrollment, is one of 5 that started in 2020, is one of 3 in phase 1/2, and was the 2nd registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

4 of the 54 studies testing BNT162 Vaccine in COVID-19 are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About BNT162 Vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing BNT162 Vaccine in COVID-19, or all of them as a file.
02

Study summary

Originally, the study was planned to include two parts, i.e., Part A and Part B, however Part B was cancelled due to changes in the overall clinical development plan. The objectives originally described for Part B have been implemented in the ongoing development via a pivotal Phase I/II/III trial BNT162-02/C4591001 (ClinicalTrials.gov NCT: 04368728).

The conducted Part A was a dose-finding part to investigate the optimal dose of four different vaccines (BNT162a1, BNT162b1, BNT162b2, and BNT162c2), allowing dose adjustments upwards and downwards in younger participants. Doses tested in older participants and expansion cohorts were chosen based on acceptability of dosing in younger participants.

The vaccines BNT162a1, BNT162b1, BNT162b2, and BNT162c2 were administered using a Prime/Boost (P/B) regimen with two doses given \~21 days apart. The vaccine BNT162c2 was also administered using a Single dose (SD) regimen. Four additional expansion cohorts (cohorts 11, 12, 13, and 14) aged from 18 to 85 years received BNT162b2 using a P/B regimen only. In cohort 11, participants received BNT162b2 using one 3 μg prime dose (Dose 1) and one 30 μg boost dose (Dose 2) of BNT162b2. Participants in cohorts 12, 13, and 14 received two doses of BNT162b2 30 µg, each.

Read the detailed description

This study was a multi-site, Phase I/II, open-label, dose-escalation study. The study included the first-in-human (FIH) dose and dose ranging groups for all four vaccines in healthy younger participants (aged 18 to 55 years [years]) and older participants (aged 56 to 85 years). The conducted Part A followed a dose escalation design. Discretionary dose de-escalation and refinement was also planned. Study participants with the FIH immunization and any subsequent dose escalation cohorts were immunized using a sentinel dosing/subject staggering. For any dose de-escalation or dose-refinement cohorts in younger adults, i.e., cohorts with doses lower than previously tested, participants were dosed using a subject staggering process. Cohorts in older participants were optional and dependent on acceptability of dosing in younger participants. Part A consisted of a treatment phase and a follow-up phase.

For the BNT162a1 3 µg arm, the Safety Review Committee (SRC) decided to stop dosing after 6 treated participants and to not administer the boost immunization (Dose 2). For the BNT162b1 60 µg arm, the SRC decided to not administer the boost immunization (Dose 2) for the 12 participants.

03

Conditions studied

  • Infections, Respiratory
  • Virus Diseases
  • Infection Viral
  • Vaccine Adverse Reaction
  • RNA Virus Infections
  • Protection Against COVID-19 and Infections With SARS CoV 2

Keywords

  • SARS-CoV-2
  • Severe Acute Respiratory Syndrome (SARS)
  • Coronavirus Disease 2019
  • COVID-2019
  • Virus Diseases
04

In context

COVID-19 Reclassified

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

This study's enrollment of 512 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

BioNTech SE is the lead sponsor of 76 studies on the registry; 25 are open to participants now.

Of its 33 completed or terminated interventional studies of FDA-regulated products, 26 (79%) have results posted.

Compared within COVID-19, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Respiratory Tract Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have given by signing the informed consent form (ICF) before initiation of any trial-specific procedures.
  • They must be willing and able to comply with scheduled visits, treatment schedule, laboratory tests, lifestyle restrictions (e.g., to practice social distancing and to follow good practices to reduce their chances of being infected or spreading COVID-19), and other requirements of the trial.
  • They must be able to understand and follow trial-related instructions.
  • For younger adult cohorts, volunteers must be aged 18 to 55 years, have a (BMI) over 19 kg/m\^2 and under 30 kg/m\^2, and weigh at least 50 kg at Visit 0. OR For older adult cohorts, volunteers must be aged 56 to 85 years, have a BMI over 19 kg/m\^2 and under 30 kg/m\^2, and weigh at least 50 kg at Visit 0. OR For the adult cohort (Cohort 13), volunteers must be aged 18 to 85 years, have a BMI over 19 kg/m\^2 and under 30 kg/m\^2, and weigh at least 50 kg at Visit 0.
  • They must be healthy, in the clinical judgment of the investigator, based on medical history, physical examination, 12-lead (ECG), vital signs (systolic/diastolic blood pressure, pulse rate, body temperature, respiratory rate), and clinical laboratory tests (blood chemistry, hematology, and urine chemistry) at Visit 0. Note: Healthy volunteers with pre-existing stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included. OR For the immunocompromised cohort (Cohort 13); volunteers who have previously received solid organ transplant, or peripheral blood stem cell transplantation ≥6 months after transplantation, or individuals with (HIV) infection with a of ≥200 x 10\^6 /L at Visit 0. Individuals with lower T-cell counts will be excluded from the trial on the basis that this represents a significant medical complication. In the clinical judgment of the investigator, volunteers must be immunocompromised but otherwise healthy. After consultation with the Medical Monitor, this may include individuals receiving immunosuppressant therapy due to another confounding disease at least 2 weeks prior to enrollment and/or at least 6 weeks following immunization with BNT162b2, and/or individuals with immunosuppressive treatment of an disease if the disease is stable.
  • Women of (WOCBP) must have a negative beta-human chorionic gonadotropin urine test at Visit 0 and Visit 1. Women that are or permanently sterilized will be considered as not having .
  • WOCBP must agree to practice a highly effective form of during the trial, starting after Visit 0 and continuously until 60 days after receiving the last immunization. WOCBP must agree to require their male partners to use condoms during sexual contact (unless male partners are sterilized or infertile).
  • WOCBP must confirm that they practice at least one highly effective form of contraception for the 14 days prior to Visit 0.
  • WOCBP must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during trial, starting after Visit 0 and continuously until 60 days after receiving the last immunization.
  • Men who are sexually active with a WOCBP and have not had a vasectomy must agree to practice a highly effective form of contraception with their female partner of childbearing potential during the trial, starting after Visit 0 and continuously until 60 days after receiving the last immunization.
  • Men must be willing to refrain from sperm donation, starting after Visit 0 and continuously until 60 days after receiving the last immunization.
  • They must have confirmation of their health insurance coverage prior to Visit 0.
  • They must agree to not be vaccinated during the trial, starting after Visit 0 and continuously until 28 days after receiving the last immunization.

Exclusion criteria

Exclusion Criteria:

  • Have had any acute illness, as determined by the investigator, with or without fever, within 72 hours prior to the first immunization. An acute illness which is nearly resolved with only minor residual symptoms remaining is allowable if, in the opinion of the investigator, the residual symptoms will not compromise their well-being if they participate as trial subjects in the trial, or that could prevent, limit, or confound the protocol-specified assessments.
  • Are breastfeeding on the day of Visit 0 or who plan to breastfeed during the trial, starting after Visit 0 and continuously until at least 90 days after receiving the last immunization.
  • Have a known allergy, , or intolerance to the planned medicinal product (IMP) including any of the IMP.
  • Had any medical condition or any major surgery (e.g., requiring general anesthesia) within the past 5 years which, in the opinion of the investigator, could compromise their well-being if they participate as trial subjects in the trial, or that could prevent, limit, or confound the protocol-specified assessments.
  • Have any surgery planned during the trial, starting after Visit 0 and continuously until at least 90 days after receiving the last immunization.
  • Had any chronic use (more than 21 continuous days) of any systemic medications, including 's or other immune-modifying drugs (except for Cohort 13), within the 6 months prior to Visit 0 unless in the opinion of the investigator, the medication would not prevent, limit, or confound the protocol-specified assessments or could compromise subject safety. Note: Healthy volunteers with pre-existing stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included.
  • Had any vaccination within the 28 days prior to Visit 0.
  • Had administration of any immunoglobulins and/or any blood products within the 3 months prior to Visit 0.
  • Had administration of another investigational medicinal product including vaccines within 60 days or 5 half-lives (whichever is longer), prior to Visit 0.
  • Have a known history of active or ongoing or infection; or except for Cohort 13: -1 or HIV-2 infection within the 30 days prior to Visit 0.
  • Have a positive polymerase chain reaction (PCR)-based test for SARS-CoV-2 within the 30 days prior to Visit 1.
  • Have a positive drugs of abuse (for amphetamines, benzodiazepines, barbiturates, cocaine, cannabinoids, opiates, methadone, methamphetamines, phencyclidine, and tricyclic antidepressants) result at Visit 0 or Visit 1.
  • Have a positive breath alcohol test at Visit 0 or Visit 1.
  • Previously participated in an investigational trial involving lipid nanoparticles.
  • Are subject to exclusion periods from other investigational trials or simultaneous participation in another clinical trial. When entering the follow-up phase, i.e., after completing the end of treatment (EoT) visit, subjects are allowed to participate in other clinical trials not investigating COVID-19 vaccines or treatments; subjects immunized with BNT162 vaccines in this clinical trial are allowed to participate in other clinical trials involving immunization with BNT162b2.
  • Have any affiliation with the trial site (e.g., are close relative of the investigator or dependent person, such as an employee or student of the trial site).
  • Have a history (within the past 5 years) of substance abuse or known medical, psychological, or social conditions which, in the opinion of the investigator, could compromise their well-being if they participate as trial subjects in the trial, or that could prevent, limit, or confound the protocol-specified assessments.
  • Have a history of hypersensitivity or serious reactions to previous vaccinations.
  • Have a history of Guillain-Barré Syndrome within 6 weeks following a previous vaccination.
  • Have a history of narcolepsy.
  • Have history of alcohol abuse or drug addiction within 1 year before Visit 0.
  • (Except for Cohort 13) Have a history of or suspected immunosuppressive condition, acquired or congenital, as determined by medical history and/or physical examination at Visit 0.
  • Have any abnormality or permanent body art (e.g., tattoo) that, in the opinion of the investigator, would obstruct the ability to observe local reactions at the injection site.
  • Have had any blood loss >450 mL, e.g., due to donation of blood or blood products or injury, within the 7 days prior to Visit 0 or plan to donate blood during the trial, starting after Visit 0 and continuously until at least 7 days after receiving the last immunization.
  • Have symptoms of COVID-19, e.g., respiratory symptoms, fever, cough, shortness of breath and breathing difficulties.
  • Have had contact with persons diagnosed with COVID-19 or who tested positive for SARS-CoV-2 by any diagnostic test within the 30 days prior to Visit 1.
  • Are soldiers, volunteers in detention, contract research organization (CRO) or sponsor staff or their family members.
  • Regular receipt of inhaled/nebulized (except for Cohort 13).
  • For older volunteers and for Cohort 13 only: Have a condition known to put them at high risk for severe COVID-19, including those with any of the following risk factors:
  • Uncontrolled hypertension.
  • Diabetes mellitus ( >8.5% ≥3 months, according to the medical history reported by the subject).
  • .
  • Asthma.
  • Chronic liver disease.
  • Known Stage 3 or worse chronic kidney disease ( \<60 mL/min/1.73 m\^2); Except for post-renal transplant patients who should have (estimated) GFR ≥40 mL/min/1.73 m\^2.
  • Serious heart conditions, such as heart failure, coronary artery disease, or cardiomyopathies.
  • Sickle cell disease.
  • Cancer (except for Cohort 13).
  • Are immune compromised due to stem cell or organ-transplantation with significant medical complications such as acute or chronic graft rejection or requiring intensive immunosuppressive treatment, transplant failure or infectious complications or other conditions that would be considered a for vaccination.
  • Are immune compromised due to HIV infection with a of \< 200 x 10\^6 /L at screening or significant medical complications such as opportunistic infections, malignant complications (e.g., lymphoma, Kaposi sarcoma), other organ manifestations consistent with advanced AIDS or other conditions that would be considered a contraindication for vaccination.
  • Resident in a long term facility.
  • Current vaping or smoking (occasional smoking is acceptable).
  • History of chronic smoking within the prior year.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
512 participants (actual)

Study arms

  • Experimental
    BNT162a1 (P/B) - Part A 18-55 years of age

    Escalating dose levels

    Biological: BNT162a1

  • Experimental
    BNT162b1 (P/B) - Part A 18-55 years of age

    Escalating dose levels

    Biological: BNT162b1

  • Experimental
    BNT162b2 (P/B) - Part A 18-55 years of age

    Escalating dose levels

    Biological: BNT162b2

  • Experimental
    BNT162c2 (P/B) - Part A 18-55 years of age

    Escalating dose levels

    Biological: BNT162c2

  • Experimental
    BNT162c2 (prime only) - Part A 18-55 years of age

    Single dose

    Biological: BNT162c2

  • Experimental
    BNT162b1 (P/B) - Part A 56-85 years of age

    Escalating dose levels

    Biological: BNT162b1

  • Experimental
    BNT162b2 (P/B) - Part A 56-85 years of age

    Escalating dose levels

    Biological: BNT162b2

  • Experimental
    BNT162b2 (P/B) - Part A 18-85 years of age (Expansion cohorts 11 to 13)

    Fixed doses used; cohort 11: alternative posology dose group expansion cohort; cohort 12: adaptive immune response dose group expansion cohort; cohort 13: immunocompromised (IC) participants expansion cohort

    Biological: BNT162b2

  • Experimental
    BNT162b2 (P/B) - Part A 18-85 years of age (Expansion cohort 14)

    fixed doses used; B-cell immune response dose group expansion cohort

    Biological: BNT162b2

Interventions

  • BiologicalBNT162a1

    Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.

  • BiologicalBNT162b1

    Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.

  • BiologicalBNT162b2

    Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.

  • BiologicalBNT162c2

    Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.

07

What researchers measure

Primary outcomes

  1. Number of Participants With Solicited Local Reactions at the Injection Site (Pain, Tenderness, Erythema/Redness, Induration/Swelling) Recorded up to 7 Days After Each IMP Dose.

    Solicited local reactions at the injection site (pain, tenderness, erythema/redness, and induration/swelling) were monitored and graded using criteria based on the guidance given in US FDA Guidance for Industry "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials". The reporting of local reactions was based on the participant's assessments via daily solicited reports in the participant diaries.

    Time frame: From Day 1 to Day 8 for Dose 1 (Prime Immunization) and from Day 22 to Day 29 for Dose 2 (Boost Immunization)

  2. Number of Participants With Solicited Systemic Reactions (Nausea, Vomiting, Diarrhea, Headache, Fatigue, Myalgia, Arthralgia, Chills, Loss of Appetite, Malaise, and Fever) Recorded up to 7 Days After Each IMP Dose.

    Solicited systemic reactions (nausea, vomiting, diarrhea, headache, fatigue, myalgia, arthralgia, chills, loss of appetite, malaise, and fever) were monitored and graded using criteria based on the guidance given in US FDA Guidance for Industry "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials". The reporting of systemic reactions was based on the participant's assessments via daily solicited reports in the participant diaries.

    Time frame: From Day 1 to Day 8 for Dose 1 (Prime Immunization) and from Day 22 to Day 29 for Dose 2 (Boost Immunization)

  3. The Percentage of Participants With at Least 1 Unsolicited Treatment Emergent Adverse Event (TEAE) Occurring After Dose 1 (Prime Immunization) up to Dose 2 (Boost Immunization) or 28 Days After Dose 1.

    TEAEs without AEs based on solicited reporting via diaries, were analyzed by vaccine, age group, dose level, and for each IMP dose. The percentage of participants reporting at least one TEAE was summarized by adverse event types (any TEAE and any grade \>=3 TEAE) using the Safety Set.

    Time frame: 28 days following Dose 1 or up to Dose 2 (whichever was first)

  4. The Percentage of Participants With at Least 1 Unsolicited TEAE Occurring After Dose 1 up to 28 Days After Dose 2 (Boost Immunization) or After Dose 1 (Prime Immunization) (if no Dose 2)

    TEAEs, without AEs based on solicited reporting via diaries, were analyzed by vaccine, age group, dose level, and for each IMP dose. The percentage of participants reporting at least one TEAE was summarized by adverse event types (any TEAE and any grade \>=3 TEAE) using the Safety Set.

    Time frame: 28 days following Dose 2 or Dose 1 (if no Dose 2 was given)

Secondary outcomes

  1. Functional Antibody Responses (Titers) for BNT162a1, BNT162b1, BNT162b2 (Younger and Older Dose Ranging Cohorts), and BNT162c2 (P/B)

    At Day 1 (Baseline = Pre-Prime Immunization) and at 7 and 21 days after Dose 1 (Prime Immunization) and at 7, 21, 28, 63, and 162 days after Dose 2 (Boost Immunization).

    Time frame: up to 183 days following Dose 1

  2. Fold Increase in Functional Antibody Titers as Compared to Baseline for BNT162a1, BNT162b1, BNT162b2 (Younger and Older Dose Ranging Cohorts), and BNT162c2 (P/B)

    At 7 and 21 days after Dose 1 (Prime Immunization) and at 7, 21, 28, 63, and 162 days after Dose 2 (Boost Immunization).

    Time frame: up to 183 days following Dose 1

  3. Number of Participants With Seroconversion Defined as a Minimum of 4-fold Increase of Functional Antibody Titers as Compared to Baseline for BNT162a1, BNT162b1, BNT162b2 (Younger and Older Dose Ranging Cohorts), and BNT162c2 (P/B)

    At 7 and 21 days after Dose 1 (Prime Immunization) and at 7, 21, 28, 63, and 162 days after Dose 2 (Boost Immunization).

    Time frame: up to 183 days following Dose 1

  4. Functional Antibody Responses (Titers) for BNT162c2 (SD)

    At Day 1 (Baseline = Pre Immunization) and at 7, 21, 28, 42, 84, and 183 days after Dose 1 (Prime Immunization).

    Time frame: up to 183 days following Dose 1

  5. Fold Increase in Functional Antibody Titers as Compared to Baseline for BNT162c2 (SD)

    At 7, 21, 28, 42, 84, and 183 days after Dose 1 (Prime Immunization).

    Time frame: up to 183 days following Dose 1

  6. Number of Participants With Seroconversion Defined as a Minimum of 4-fold Increase of Functional Antibody Titers as Compared to Baseline for BNT162c2 (SD)

    At 7, 21, 28, 42, 84, and 183 days after Dose 1 (Prime Immunization).

    Time frame: up to 183 days following Dose 1

  7. Functional Antibody Responses (Titers) for BNT162b2 (Expansion Cohorts 11, 12, 13, and 14; P/B)

    At Day 1 (Baseline = Pre-Prime Immunization) and at 7, 14, and 21 days after Dose 1 (Prime Immunization) and at 7, 14, 21, 28, 63, 162, and 343 days after Dose 2 (Boost Immunization).

    Time frame: up to 1 year following Dose 1

  8. Fold Increase in Functional Antibody Titers as Compared to Baseline for BNT162b2 (Expansion Cohorts 11, 12, 13, and 14; P/B)

    At 7, 14, and 21 days after Dose 1 (Prime Immunization) and at 7, 14, 21, 28, 63, 162, and 343 days after Dose 2 (Boost Immunization).

    Time frame: up to 1 year following Dose 1

  9. Number of Participants With Seroconversion Defined as a Minimum of 4-fold Increase of Functional Antibody Titers as Compared to Baseline for BNT162b2 (Expansion Cohorts 11, 12, 13, and 14; P/B)

    At 7, 14, and 21 days after Dose 1 (Prime Immunization) and at 7, 14, 21, 28, 63, 162, and 343 days after Dose 2 (Boost Immunization).

    Time frame: up to 1 year following Dose 1

08

Results

Posted Jul 12, 2024

Participant flow

Study participants were selected from the volunteer panel at the clinical CRO, volunteers who responded to either generic or study-specific advertisements in social media, or volunteers who contacted the clinical CRO via a web-based study participant recruitment portal. Study participants were selected from this pool of volunteers according to inclusion and exclusion criteria. The first participant was enrolled on 23 APR 2020.

Participant flow — Overall Study
MilestoneBNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μgBNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μgBNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μgBNT162b2 - Part A Immunocompromised (IC) Participants Aged 18 to 85 Years - 30 μg HIV (Cohort 13)BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg Post-transplant (Cohort 13)BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg (Cohort 11)BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 12)BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 14)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg Single Dose (SD)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (SD)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.6 μg (SD)BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (SD)
Started1212612121212121212121212121212121212121215153090201212121212121212
Completed end of treatment1212612121110111112121212111211121212121215153089191212121112121112
Completed end of follow-up phase121261212111011111112111211121111121211110000191212121012121111
Completed121261212111011111112111211121111121211110000191212121012121111
Not completed00000121110101011001115153090100020011
Withdrew: Pregnancy0000000000000000000000000000000010
Withdrew: Lost to follow-up0000000000000000000010010000010001
Withdrew: Private reason(s)0000001011000000000000010000010000
Withdrew: Withdrawal by subject0000001100010100100000221100000000
Withdrew: Adverse event0000010000000001000100000000000000
Withdrew: Roll-over into trial bnt162-1400000000000000000000011111031000000000
Withdrew: Physician decision0000000000000000000000002000000000
Withdrew: Death0000000000000000000000001000000000
Withdrew: Non-trial sars-cov-2 vaccination due to covid-19000000000000000000000421655000000000

Outcome measures

PrimaryNumber of Participants With Solicited Local Reactions at the Injection Site (Pain, Tenderness, Erythema/Redness, Induration/Swelling) Recorded up to 7 Days After Each IMP Dose.

Solicited local reactions at the injection site (pain, tenderness, erythema/redness, and induration/swelling) were monitored and graded using criteria based on the guidance given in US FDA Guidance for Industry "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials". The reporting of local reactions was based on the participant's assessments via daily solicited reports in the participant diaries.

Time frame:
From Day 1 to Day 8 for Dose 1 (Prime Immunization) and from Day 22 to Day 29 for Dose 2 (Boost Immunization)
Reported as:
Count of participants · Participants
Number of Participants With Solicited Local Reactions at the Injection Site (Pain, Tenderness, Erythema/Redness, Induration/Swelling) Recorded up to 7 Days After Each IMP Dose.
ParticipantsBNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μgBNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μgBNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μgBNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg HIV (Cohort 13)BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg Post-transplant (Cohort 13)BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg (Cohort 11)BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 12)BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 14)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (SD)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (SD)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.6 μg (SD)BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (SD)
Prime up to Day 7 after Prime: Number of participants with any local reaction9116651012111212711116912121079912141682204381147511
Prime up to Day 7 after Prime: Number of participants with any severe/grade >= 3 local reaction0000012421000000000000001000000000
Boost up to Day 7 after Boost: Number of participants with any local reaction310—7510111111—89948101011781012112779193578————
Boost up to Day 7 after Boost: Number of participants with any severe/grade >= 3 local reaction00—200023—00000000101002210000————
PrimaryNumber of Participants With Solicited Systemic Reactions (Nausea, Vomiting, Diarrhea, Headache, Fatigue, Myalgia, Arthralgia, Chills, Loss of Appetite, Malaise, and Fever) Recorded up to 7 Days After Each IMP Dose.

Solicited systemic reactions (nausea, vomiting, diarrhea, headache, fatigue, myalgia, arthralgia, chills, loss of appetite, malaise, and fever) were monitored and graded using criteria based on the guidance given in US FDA Guidance for Industry "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials". The reporting of systemic reactions was based on the participant's assessments via daily solicited reports in the participant diaries.

Time frame:
From Day 1 to Day 8 for Dose 1 (Prime Immunization) and from Day 22 to Day 29 for Dose 2 (Boost Immunization)
Reported as:
Count of participants · Participants
Number of Participants With Solicited Systemic Reactions (Nausea, Vomiting, Diarrhea, Headache, Fatigue, Myalgia, Arthralgia, Chills, Loss of Appetite, Malaise, and Fever) Recorded up to 7 Days After Each IMP Dose.
ParticipantsBNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μgBNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μgBNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μgBNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg HIV (Cohort 13)BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg Post-transplant (Cohort 13)BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg (Cohort 11)BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 12)BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 14)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (SD)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (SD)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.6 μg (SD)BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (SD)
Prime up to Day 7 after Prime: Number of participants with any systemic reaction612698811111212910119912993491214126815589127748
Prime up to Day 7 after Prime: Number of participants with any severe / grade >= 3 systemic reaction1150012358112000101001005000110202
Boost up to Day 7 after Boost: Number of participants with any systemic reaction312—779101111—810124271010481113122178163769————
Boost up to Day 7 after Boost: Number of participants with any severe / grade >= 3 systemic reaction04—315565—224001131024141431102————
PrimaryThe Percentage of Participants With at Least 1 Unsolicited Treatment Emergent Adverse Event (TEAE) Occurring After Dose 1 (Prime Immunization) up to Dose 2 (Boost Immunization) or 28 Days After Dose 1.

TEAEs without AEs based on solicited reporting via diaries, were analyzed by vaccine, age group, dose level, and for each IMP dose. The percentage of participants reporting at least one TEAE was summarized by adverse event types (any TEAE and any grade \>=3 TEAE) using the Safety Set.

Time frame:
28 days following Dose 1 or up to Dose 2 (whichever was first)
Reported as:
Number · percentage of participants
The Percentage of Participants With at Least 1 Unsolicited Treatment Emergent Adverse Event (TEAE) Occurring After Dose 1 (Prime Immunization) up to Dose 2 (Boost Immunization) or 28 Days After Dose 1.
percentage of participantsBNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μgBNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μgBNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μgBNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg HIV (Cohort 13)BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg Post-transplant (Cohort 13)BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg (Cohort 11)BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 12)BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 14)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (SD)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (SD)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.6 μg (SD)BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (SD)
Any TEAE833838050334242582517582550508422533257531326351733171750582525
Any grade >=3 TEAE00000080008880080000170702500080000
PrimaryThe Percentage of Participants With at Least 1 Unsolicited TEAE Occurring After Dose 1 up to 28 Days After Dose 2 (Boost Immunization) or After Dose 1 (Prime Immunization) (if no Dose 2)

TEAEs, without AEs based on solicited reporting via diaries, were analyzed by vaccine, age group, dose level, and for each IMP dose. The percentage of participants reporting at least one TEAE was summarized by adverse event types (any TEAE and any grade \>=3 TEAE) using the Safety Set.

Time frame:
28 days following Dose 2 or Dose 1 (if no Dose 2 was given)
Reported as:
Number · percentage of participants
The Percentage of Participants With at Least 1 Unsolicited TEAE Occurring After Dose 1 up to 28 Days After Dose 2 (Boost Immunization) or After Dose 1 (Prime Immunization) (if no Dose 2)
percentage of participantsBNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μgBNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μgBNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μgBNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg HIV (Cohort 13)BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg Post-transplant (Cohort 13)BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg (Cohort 11)BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 12)BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 14)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg (P/B)
Any TEAE17338358875505867582533755858672550335833137340494533423317
Any grade >=3 TEAE0000002500088170080088170734100808
SecondaryFunctional Antibody Responses (Titers) for BNT162a1, BNT162b1, BNT162b2 (Younger and Older Dose Ranging Cohorts), and BNT162c2 (P/B)

At Day 1 (Baseline = Pre-Prime Immunization) and at 7 and 21 days after Dose 1 (Prime Immunization) and at 7, 21, 28, 63, and 162 days after Dose 2 (Boost Immunization).

Time frame:
up to 183 days following Dose 1
Reported as:
Geometric mean · titer
Functional Antibody Responses (Titers) for BNT162a1, BNT162b1, BNT162b2 (Younger and Older Dose Ranging Cohorts), and BNT162c2 (P/B)
titerBNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μgBNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μgBNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μgBNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg (P/B)
Day 1 (Baseline = Pre-Prime Immunization)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)5.1 (4.8 to 5.5)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)6.9 (3.4 to 13.8)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)
7 days after Dose 1 (Day 8)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)5.1 (4.8 to 5.5)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)8.2 (2.8 to 24.1)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)
21 days after Dose 1 (Day 22)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)10.0 (6.1 to 16.3)6.9 (4.4 to 10.7)10.0 (5.4 to 18.5)11.7 (6.2 to 22.1)29.1 (13.5 to 63.0)20.6 (11.5 to 37.0)13.7 (7.5 to 25.3)16.3 (7.7 to 34.5)15.4 (7.8 to 30.4)16.3 (8.3 to 32.3)5.3 (4.7 to 6.0)7.5 (5.6 to 10.1)16.6 (9.7 to 28.3)16.3 (8.0 to 33.5)15.9 (9.6 to 26.2)8.4 (5.6 to 12.6)7.9 (5.2 to 12.1)49.0 (18.3 to 131.4)5.0 (5.0 to 5.0)5.3 (4.7 to 6.0)5.3 (4.7 to 6.0)7.1 (4.9 to 10.2)
7 days after Dose 2 (Day 29)————55.0 (32.5 to 93.1)—181.5 (107.5 to 306.3)———320.0 (183.6 to 557.7)169.5 (70.3 to 408.7)207.5 (94.0 to 458.0)38.9 (16.1 to 93.5)134.5 (82.2 to 220.1)40.0 (NA to NA)213.6 (114.7 to 397.7)329.4 (203.2 to 533.9)127.0 (79.2 to 203.7)164.7 (77.0 to 352.0)678.1 (395.9 to 1161.2)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)5.3 (4.7 to 6.0)8.0 (4.8 to 13.4)
21 days after Dose 2 (Day 43)5.0 (5.0 to 5.0)8.7 (3.8 to 19.8)5.3 (4.6 to 6.1)69.2 (33.0 to 145.4)95.1 (47.0 to 192.7)62.2 (30.4 to 127.0)160.0 (90.3 to 283.6)184.9 (96.8 to 353.0)282.1 (136.8 to 581.6)8.9 (6.1 to 13.0)293.4 (179.9 to 478.5)95.1 (42.3 to 214.0)134.5 (66.8 to 270.8)49.9 (26.9 to 92.6)109.9 (71.1 to 169.8)187.3 (119.9 to 292.6)164.7 (89.3 to 303.6)300.5 (182.7 to 494.1)134.5 (84.5 to 214.1)169.5 (115.3 to 249.2)452.5 (255.6 to 801.1)5.1 (4.8 to 5.5)5.6 (4.9 to 6.5)5.7 (4.8 to 6.6)6.0 (4.6 to 8.0)
28 days after Dose 2 (Day 50)5.0 (NA to NA)———80.0 (36.1 to 177.5)—82.3 (37.4 to 181.1)———226.3 (120.5 to 424.8)89.8 (37.5 to 214.9)95.1 (50.9 to 178.0)36.4 (20.8 to 63.8)67.3 (35.7 to 126.7)190.3 (118.4 to 305.7)160.0 (84.6 to 302.5)213.6 (148.8 to 306.6)127.0 (75.7 to 213.0)132.4 (91.8 to 191.0)391.7 (229.4 to 668.8)5.0 (5.0 to 5.0)5.9 (5.0 to 7.1)5.0 (5.0 to 5.0)5.3 (4.7 to 6.0)
63 days after Dose 2 (Day 85)5.0 (5.0 to 5.0)7.5 (3.9 to 14.5)5.0 (5.0 to 5.0)25.9 (14.6 to 46.0)31.7 (14.5 to 69.4)40.0 (21.1 to 76.0)134.5 (70.0 to 258.6)102.9 (58.1 to 182.2)120.5 (56.1 to 258.7)7.7 (5.2 to 11.4)46.2 (25.4 to 84.0)33.6 (16.6 to 68.1)69.2 (33.8 to 142.0)36.4 (19.3 to 68.6)33.6 (19.9 to 57.0)145.6 (85.5 to 247.8)146.7 (80.9 to 265.9)160.0 (97.4 to 263.0)21.8 (12.1 to 39.2)27.4 (17.5 to 42.9)80.0 (39.1 to 163.5)5.6 (5.0 to 6.3)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)5.2 (4.7 to 5.8)
162 days after Dose 2 (Day 184)5.0 (5.0 to 5.0)6.9 (3.4 to 13.8)5.0 (5.0 to 5.0)10.0 (6.1 to 16.4)15.0 (9.0 to 24.8)13.7 (8.8 to 21.4)27.4 (14.0 to 53.6)29.2 (13.9 to 61.2)56.6 (22.3 to 143.6)5.2 (4.8 to 5.5)16.8 (10.0 to 28.2)19.4 (10.7 to 35.1)65.4 (31.7 to 134.8)8.5 (5.6 to 13.0)11.2 (7.8 to 16.2)21.3 (12.2 to 37.3)54.8 (31.5 to 95.5)38.9 (20.6 to 73.2)26.7 (14.1 to 50.4)15.5 (11.8 to 20.5)58.4 (30.6 to 111.3)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)5.8 (4.2 to 7.9)10.4 (3.4 to 31.5)
SecondaryFold Increase in Functional Antibody Titers as Compared to Baseline for BNT162a1, BNT162b1, BNT162b2 (Younger and Older Dose Ranging Cohorts), and BNT162c2 (P/B)

At 7 and 21 days after Dose 1 (Prime Immunization) and at 7, 21, 28, 63, and 162 days after Dose 2 (Boost Immunization).

Time frame:
up to 183 days following Dose 1
Reported as:
Geometric mean · Fold rise
Fold Increase in Functional Antibody Titers as Compared to Baseline for BNT162a1, BNT162b1, BNT162b2 (Younger and Older Dose Ranging Cohorts), and BNT162c2 (P/B)
Fold riseBNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μgBNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μgBNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μgBNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg (P/B)
7 days after Dose 1 (Day 8)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)1.2 (0.8 to 1.7)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)
21 days after Dose 1 (Day 22)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)2.0 (1.2 to 3.3)1.4 (0.9 to 2.1)2.0 (1.1 to 3.7)2.3 (1.2 to 4.4)5.8 (2.7 to 12.6)4.0 (2.2 to 7.3)2.7 (1.5 to 5.1)3.3 (1.5 to 6.9)3.1 (1.6 to 6.1)3.3 (1.7 to 6.5)1.1 (0.9 to 1.2)1.5 (1.1 to 2.0)3.3 (1.9 to 5.7)3.3 (1.6 to 6.7)3.2 (1.9 to 5.2)1.7 (1.1 to 2.5)1.6 (1.0 to 2.4)7.1 (4.3 to 11.9)1.0 (1.0 to 1.0)1.1 (0.9 to 1.2)1.1 (0.9 to 1.2)1.4 (1.0 to 2.0)
7 days after Dose 2 (Day 29)————11.0 (6.5 to 18.6)—36.3 (21.5 to 61.3)———64.0 (36.7 to 111.5)33.9 (14.1 to 81.7)41.5 (18.8 to 91.6)7.8 (3.2 to 18.7)26.9 (16.4 to 44.0)8.0 (NA to NA)42.7 (22.9 to 79.5)65.9 (40.6 to 106.8)25.4 (15.8 to 40.7)32.9 (15.4 to 70.4)98.7 (62.2 to 156.5)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)1.1 (0.9 to 1.2)1.6 (1.0 to 2.7)
21 days after Dose 2 (Day 43)1.0 (1.0 to 1.0)1.7 (0.8 to 4.0)1.1 (0.9 to 1.2)13.8 (6.6 to 29.1)19.0 (9.4 to 38.5)12.4 (6.1 to 25.4)32.0 (18.1 to 56.7)37.0 (19.4 to 70.6)54.7 (26.5 to 112.8)1.8 (1.2 to 2.6)58.7 (36.0 to 95.7)19.0 (8.5 to 42.8)26.9 (13.4 to 54.2)10.0 (5.4 to 18.5)22.0 (14.2 to 34.0)37.5 (24.0 to 58.5)32.9 (17.9 to 60.7)60.1 (36.5 to 98.8)26.9 (16.9 to 42.8)33.9 (23.1 to 49.8)65.9 (45.5 to 95.3)1.0 (1.0 to 1.1)1.1 (1.0 to 1.3)1.1 (1.0 to 1.3)1.2 (0.9 to 1.6)
28 days after Dose 2 (Day 50)1.0 (NA to NA)———16.0 (7.2 to 35.5)—16.5 (7.5 to 36.2)———45.3 (24.1 to 85.0)18.0 (7.5 to 43.0)19.0 (10.2 to 35.6)7.3 (4.2 to 12.8)13.5 (7.1 to 25.3)38.1 (23.7 to 61.1)32.0 (16.9 to 60.5)42.7 (29.8 to 61.3)25.4 (15.1 to 42.6)26.5 (18.4 to 38.2)57.0 (38.6 to 84.3)1.0 (1.0 to 1.0)1.2 (1.0 to 1.4)1.0 (1.0 to 1.0)1.1 (0.9 to 1.2)
63 days after Dose 2 (Day 85)1.0 (1.0 to 1.0)1.5 (0.8 to 2.9)1.0 (1.0 to 1.0)5.2 (2.9 to 9.2)6.3 (2.9 to 13.9)8.0 (4.2 to 15.2)26.9 (14.0 to 51.7)20.6 (11.6 to 36.4)23.4 (10.8 to 50.4)1.5 (1.0 to 2.3)9.2 (5.1 to 16.8)6.7 (3.3 to 13.6)13.8 (6.8 to 28.4)7.3 (3.9 to 13.7)6.7 (4.0 to 11.4)29.1 (17.1 to 49.6)29.3 (16.2 to 53.2)32.0 (19.5 to 52.6)4.4 (2.4 to 7.8)5.5 (3.5 to 8.6)11.6 (7.3 to 18.7)1.1 (1.0 to 1.3)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)1.0 (0.9 to 1.2)
162 days after Dose 2 (Day 184)1.0 (1.0 to 1.0)1.4 (0.7 to 2.8)1.0 (1.0 to 1.0)2.0 (1.2 to 3.3)3.0 (1.8 to 5.0)2.7 (1.8 to 4.3)5.5 (2.8 to 10.7)5.8 (2.8 to 12.2)11.0 (4.3 to 28.2)1.0 (1.0 to 1.1)3.4 (2.0 to 5.6)3.9 (2.1 to 7.0)13.1 (6.3 to 27.0)1.7 (1.1 to 2.6)2.2 (1.6 to 3.2)4.3 (2.4 to 7.5)11.0 (6.3 to 19.1)7.8 (4.1 to 14.6)5.3 (2.8 to 10.1)3.1 (2.4 to 4.1)11.7 (6.1 to 22.3)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)1.2 (0.8 to 1.6)2.1 (0.7 to 6.3)
SecondaryNumber of Participants With Seroconversion Defined as a Minimum of 4-fold Increase of Functional Antibody Titers as Compared to Baseline for BNT162a1, BNT162b1, BNT162b2 (Younger and Older Dose Ranging Cohorts), and BNT162c2 (P/B)

At 7 and 21 days after Dose 1 (Prime Immunization) and at 7, 21, 28, 63, and 162 days after Dose 2 (Boost Immunization).

Time frame:
up to 183 days following Dose 1
Reported as:
Count of participants · Participants
Number of Participants With Seroconversion Defined as a Minimum of 4-fold Increase of Functional Antibody Titers as Compared to Baseline for BNT162a1, BNT162b1, BNT162b2 (Younger and Older Dose Ranging Cohorts), and BNT162c2 (P/B)
ParticipantsBNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μgBNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μgBNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μgBNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg (P/B)
7 days after Dose 1 (Day 8)0000000000000000000010000
21 days after Dose 1 (Day 22)00021337765630075622100001
7 days after Dose 2 (Day 29)————11—11———121211712112121212120002
21 days after Dose 2 (Day 43)0201011910121131211129121112111212120000
28 days after Dose 2 (Day 50)0———11—11———1211129111212121211120000
63 days after Dose 2 (Day 85)0209891011111108108911121287120000
162 days after Dose 2 (Day 184)010364781005710326101174100012
SecondaryFunctional Antibody Responses (Titers) for BNT162c2 (SD)

At Day 1 (Baseline = Pre Immunization) and at 7, 21, 28, 42, 84, and 183 days after Dose 1 (Prime Immunization).

Time frame:
up to 183 days following Dose 1
Reported as:
Geometric mean · titer
Functional Antibody Responses (Titers) for BNT162c2 (SD)
titerBNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (SD)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (SD)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.6 μg (SD)BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (SD)
Day 1 (Baseline = Pre Immunization)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)
7 days after Dose 1 (Day 8)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)
21 days after Dose 1 (Day 22)5.1 (4.8 to 5.5)5.1 (4.8 to 5.5)5.3 (4.7 to 6.0)5.5 (4.8 to 6.3)
28 days after Dose 1 (Day 29)—5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)5.2 (4.8 to 5.6)
42 days after Dose 1 (Day 43)5.1 (4.8 to 5.5)5.1 (4.8 to 5.5)5.5 (4.5 to 6.6)5.1 (4.8 to 5.5)
84 days after Dose 1 (Day 85)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)6.0 (4.0 to 9.2)5.0 (5.0 to 5.0)
183 days after Dose 1 (Day 184)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)5.5 (4.5 to 6.8)6.4 (3.7 to 11.3)
SecondaryFold Increase in Functional Antibody Titers as Compared to Baseline for BNT162c2 (SD)

At 7, 21, 28, 42, 84, and 183 days after Dose 1 (Prime Immunization).

Time frame:
up to 183 days following Dose 1
Reported as:
Geometric mean · Fold rise
Fold Increase in Functional Antibody Titers as Compared to Baseline for BNT162c2 (SD)
Fold riseBNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (SD)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (SD)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.6 μg (SD)BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (SD)
7 days after Dose 1 (Day 8)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)
21 days after Dose 1 (Day 22)1.0 (1.0 to 1.1)1.0 (1.0 to 1.1)1.1 (0.9 to 1.2)1.1 (1.0 to 1.3)
28 days after Dose 1 (Day 29)—1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)1.0 (1.0 to 1.1)
42 days after Dose 1 (Day 43)1.0 (1.0 to 1.1)1.0 (1.0 to 1.1)1.1 (0.9 to 1.3)1.0 (1.0 to 1.1)
84 days after Dose 1 (Day 85)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)1.2 (0.8 to 1.8)1.0 (1.0 to 1.0)
183 days after Dose 1 (Day 184)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)1.1 (0.9 to 1.4)1.3 (0.7 to 2.3)
SecondaryNumber of Participants With Seroconversion Defined as a Minimum of 4-fold Increase of Functional Antibody Titers as Compared to Baseline for BNT162c2 (SD)

At 7, 21, 28, 42, 84, and 183 days after Dose 1 (Prime Immunization).

Time frame:
up to 183 days following Dose 1
Reported as:
Count of participants · Participants
Number of Participants With Seroconversion Defined as a Minimum of 4-fold Increase of Functional Antibody Titers as Compared to Baseline for BNT162c2 (SD)
ParticipantsBNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (SD)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (SD)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.6 μg (SD)BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (SD)
7 days after Dose 1 (Day 8)0000
21 days after Dose 1 (Day 22)0000
28 days after Dose 1 (Day 29)—000
42 days after Dose 1 (Day 43)0000
84 days after Dose 1 (Day 85)0010
183 days after Dose 1 (Day 184)0001
SecondaryFunctional Antibody Responses (Titers) for BNT162b2 (Expansion Cohorts 11, 12, 13, and 14; P/B)

At Day 1 (Baseline = Pre-Prime Immunization) and at 7, 14, and 21 days after Dose 1 (Prime Immunization) and at 7, 14, 21, 28, 63, 162, and 343 days after Dose 2 (Boost Immunization).

Time frame:
up to 1 year following Dose 1
Reported as:
Geometric mean · Titer
Functional Antibody Responses (Titers) for BNT162b2 (Expansion Cohorts 11, 12, 13, and 14; P/B)
TiterBNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg HIV (Cohort 13)BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg Post-transplant (Cohort 13)BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg (Cohort 11)BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 12)BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 14)
Day 1 (Baseline = Pre-Prime Immunization)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)5.1 (4.9 to 5.3)5.0 (5.0 to 5.0)
7 days after Dose 1 (Day 8)5.0 (5.0 to 5.0)5.0 (5.0 to 5.0)5.4 (4.8 to 6.0)5.3 (4.7 to 6.1)6.6 (4.2 to 10.4)
14 days after Dose 1 (Day 15)————9.5 (4.8 to 18.7)
21 days after Dose 1 (Day 22)17.4 (9.8 to 30.9)5.2 (4.7 to 5.8)5.7 (4.8 to 6.8)21.9 (17.5 to 27.3)17.9 (9.5 to 33.7)
7 days after Dose 2 (Day 29)167.6 (112.0 to 250.7)12.0 (5.5 to 26.4)30.7 (21.3 to 44.1)348.6 (270.8 to 448.8)286.8 (183.1 to 449.4)
14 days after Dose 2 (Day 36)206.3 (116.8 to 364.3)11.5 (5.3 to 24.8)149.3 (104.0 to 214.4)379.1 (306.0 to 469.6)—
21 days after Dose 2 (Day 43)167.6 (93.8 to 299.2)9.8 (4.8 to 19.7)119.9 (81.5 to 176.4)307.8 (250.0 to 378.9)—
28 days after Dose 2 (Day 50)136.1 (76.2 to 243.0)11.0 (5.1 to 23.7)87.7 (62.3 to 123.7)266.5 (215.9 to 328.8)103.3 (70.8 to 150.6)
63 days after Dose 2 (Day 85)50.4 (30.7 to 82.7)8.3 (5.0 to 13.7)79.1 (56.7 to 110.2)99.9 (81.3 to 122.7)—
162 days after Dose 2 (Day 184)27.0 (16.3 to 44.6)11.9 (4.0 to 35.3)19.2 (11.9 to 30.9)29.5 (23.5 to 37.1)49.8 (33.3 to 74.4)
343 days after Dose 2 (Day 365)——7.1 (NA to NA)30.2 (11.7 to 78.2)—
SecondaryFold Increase in Functional Antibody Titers as Compared to Baseline for BNT162b2 (Expansion Cohorts 11, 12, 13, and 14; P/B)

At 7, 14, and 21 days after Dose 1 (Prime Immunization) and at 7, 14, 21, 28, 63, 162, and 343 days after Dose 2 (Boost Immunization).

Time frame:
up to 1 year following Dose 1
Reported as:
Geometric mean · Fold rise
Fold Increase in Functional Antibody Titers as Compared to Baseline for BNT162b2 (Expansion Cohorts 11, 12, 13, and 14; P/B)
Fold riseBNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg HIV (Cohort 13)BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg Post-transplant (Cohort 13)BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg (Cohort 11)BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 12)BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 14)
7 days after Dose 1 (Day 8)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)1.1 (1.0 to 1.2)1.0 (1.0 to 1.1)1.3 (0.8 to 2.1)
14 days after Dose 1 (Day 15)————1.9 (1.0 to 3.7)
21 days after Dose 1 (Day 22)3.5 (2.0 to 6.2)1.0 (0.9 to 1.2)1.1 (1.0 to 1.4)4.3 (3.5 to 5.3)3.6 (1.9 to 6.7)
7 days after Dose 2 (Day 29)33.5 (22.4 to 50.1)2.4 (1.1 to 5.3)6.1 (4.3 to 8.8)68.4 (53.3 to 87.7)57.4 (36.6 to 89.9)
14 days after Dose 2 (Day 36)41.3 (23.4 to 72.9)2.3 (1.1 to 5.0)29.9 (20.8 to 42.9)74.3 (60.2 to 91.8)—
21 days after Dose 2 (Day 43)33.5 (18.8 to 59.8)2.0 (1.0 to 3.9)24.0 (16.3 to 35.3)60.4 (49.2 to 74.1)—
28 days after Dose 2 (Day 50)27.2 (15.2 to 48.6)2.2 (1.0 to 4.7)17.5 (12.5 to 24.7)52.3 (42.7 to 64.0)20.7 (14.2 to 30.1)
63 days after Dose 2 (Day 85)10.1 (6.1 to 16.5)1.7 (1.0 to 2.7)15.8 (11.3 to 22.0)19.6 (16.0 to 23.9)—
162 days after Dose 2 (Day 184)5.4 (3.3 to 8.9)2.4 (0.8 to 7.1)3.8 (2.4 to 6.2)5.8 (4.6 to 7.2)10.0 (6.7 to 14.9)
343 days after Dose 2 (Day 365)——1.4 (NA to NA)5.4 (2.1 to 13.8)—
SecondaryNumber of Participants With Seroconversion Defined as a Minimum of 4-fold Increase of Functional Antibody Titers as Compared to Baseline for BNT162b2 (Expansion Cohorts 11, 12, 13, and 14; P/B)

At 7, 14, and 21 days after Dose 1 (Prime Immunization) and at 7, 14, 21, 28, 63, 162, and 343 days after Dose 2 (Boost Immunization).

Time frame:
up to 1 year following Dose 1
Reported as:
Count of participants · Participants
Number of Participants With Seroconversion Defined as a Minimum of 4-fold Increase of Functional Antibody Titers as Compared to Baseline for BNT162b2 (Expansion Cohorts 11, 12, 13, and 14; P/B)
ParticipantsBNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg HIV (Cohort 13)BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg Post-transplant (Cohort 13)BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg (Cohort 11)BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 12)BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 14)
7 days after Dose 1 (Day 8)00112
14 days after Dose 1 (Day 15)————4
21 days after Dose 1 (Day 22)701549
7 days after Dose 2 (Day 29)154228819
14 days after Dose 2 (Day 36)1543088—
21 days after Dose 2 (Day 43)1532989—
28 days after Dose 2 (Day 50)154308919
63 days after Dose 2 (Day 85)1322884—
162 days after Dose 2 (Day 184)123126118
343 days after Dose 2 (Day 365)——010—

Adverse events

Collected over Local reactions/systemic events: within 7 days after each IMP dose; SAEs: from Day 1 (Dose 1 [Prime Immunization]) up to Day 387 (approximately 12 months after Dose 2 [Boost Immunization]); Other AEs in participants with Dose 2: All AEs from Day 1 up to Day 50 and in addition if assessed as IMP-related from Day 50 up to Day 387; Other AEs in participants without Dose 2: All AEs from Day 1 up to Day 29 and in addition if assessed as IMP-related from Day 29 up to Day 387.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μg0/12 (0%)0/12 (0%)9/12 (75%)
BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μg0/12 (0%)0/12 (0%)9/12 (75%)
BNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μg0/6 (0%)0/6 (0%)5/6 (83.3%)
BNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μg0/12 (0%)0/12 (0%)9/12 (75%)
BNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μg0/12 (0%)0/12 (0%)2/12 (16.7%)
BNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μg0/12 (0%)0/12 (0%)12/12 (100%)
BNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μg0/12 (0%)0/12 (0%)6/12 (50%)
BNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μg0/12 (0%)0/12 (0%)12/12 (100%)
BNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μg0/12 (0%)0/12 (0%)12/12 (100%)
BNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μg0/12 (0%)0/12 (0%)12/12 (100%)
BNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μg0/12 (0%)0/12 (0%)3/12 (25%)
BNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μg0/12 (0%)2/12 (16.7%)4/12 (33.3%)
BNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μg0/12 (0%)0/12 (0%)9/12 (75%)
BNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μg0/12 (0%)0/12 (0%)8/12 (66.7%)
BNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μg0/12 (0%)0/12 (0%)7/12 (58.3%)
BNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μg0/12 (0%)0/12 (0%)12/12 (100%)
BNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μg0/12 (0%)0/12 (0%)10/12 (83.3%)
BNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μg0/12 (0%)0/12 (0%)11/12 (91.7%)
BNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μg0/12 (0%)1/12 (8.3%)4/12 (33.3%)
BNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μg0/12 (0%)3/12 (25%)7/12 (58.3%)
BNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μg0/12 (0%)0/12 (0%)4/12 (33.3%)
BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg HIV (Cohort 13)0/15 (0%)0/15 (0%)3/15 (20%)
BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg Post-transplant (Cohort 13)0/15 (0%)3/15 (20%)11/15 (73.3%)
BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg (Cohort 11)0/30 (0%)0/30 (0%)13/30 (43.3%)
BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 12)1/90 (1.1%)3/90 (3.3%)48/90 (53.3%)
BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 14)0/20 (0%)1/20 (5%)9/20 (45%)
BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (P/B)0/12 (0%)0/12 (0%)4/12 (33.3%)
BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (P/B)0/12 (0%)0/12 (0%)5/12 (41.7%)
BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (P/B)0/12 (0%)0/12 (0%)4/12 (33.3%)
BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg (P/B)0/12 (0%)0/12 (0%)2/12 (16.7%)
BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (SD)0/12 (0%)0/12 (0%)10/12 (83.3%)
BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (SD)0/12 (0%)0/12 (0%)9/12 (75%)
BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.6 μg (SD)0/12 (0%)0/12 (0%)5/12 (41.7%)
BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (SD)0/12 (0%)1/12 (8.3%)11/12 (91.7%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventBNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μgBNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μgBNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μgBNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg HIV (Cohort 13)BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg Post-transplant (Cohort 13)BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg (Cohort 11)BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 12)BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 14)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (SD)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (SD)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.6 μg (SD)BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (SD)
Urinary tract infectionInfections and infestations0/120/120/60/120/120/120/120/120/120/120/120/120/120/120/120/120/120/120/120/120/120/153/150/300/900/200/120/120/120/120/120/120/120/12
SyncopeNervous system disorders0/120/120/60/120/120/120/120/120/120/120/121/120/120/120/120/120/120/120/120/120/120/150/150/300/900/200/120/120/120/120/120/120/120/12
Ankle fractureInjury, poisoning and procedural complications0/120/120/60/120/120/120/120/120/120/120/120/120/120/120/120/120/120/120/121/120/120/150/150/300/900/200/120/120/120/120/120/120/120/12
Pelvic massGeneral disorders0/120/120/60/120/120/120/120/120/120/120/121/120/120/120/120/120/120/120/120/120/120/150/150/300/900/200/120/120/120/120/120/120/120/12
Diverticulum intestinal haemorrhagicGastrointestinal disorders0/120/120/60/120/120/120/120/120/120/120/120/120/120/120/120/120/120/121/120/120/120/150/150/300/900/200/120/120/120/120/120/120/120/12
Inguinal herniaGastrointestinal disorders0/120/120/60/120/120/120/120/120/120/120/120/120/120/120/120/120/120/120/121/120/120/150/150/300/900/200/120/120/120/120/120/120/120/12
Oesophageal carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/120/120/60/120/120/120/120/120/120/120/120/120/120/120/120/120/120/120/121/120/120/150/150/300/900/200/120/120/120/120/120/120/120/12
COVID-19Infections and infestations0/120/120/60/120/120/120/120/120/120/120/120/120/120/120/120/120/120/120/120/120/120/150/150/300/900/200/120/120/120/120/120/120/121/12
Umbilical herniaGastrointestinal disorders0/120/120/60/120/120/120/120/120/120/120/120/120/120/120/120/120/120/120/120/120/120/150/150/300/901/200/120/120/120/120/120/120/120/12
CystitisInfections and infestations0/120/120/60/120/120/120/120/120/120/120/120/120/120/120/120/120/120/120/120/120/120/150/150/301/900/200/120/120/120/120/120/120/120/12
Most frequent other events
Showing 10 of 186
Most frequent other events
EventBNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μgBNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μgBNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μgBNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg HIV (Cohort 13)BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg Post-transplant (Cohort 13)BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg (Cohort 11)BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 12)BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 14)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (SD)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (SD)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.6 μg (SD)BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (SD)
Injection site reactionGeneral disorders9/128/121/64/120/128/120/1211/1212/126/120/120/120/122/120/1211/129/1210/120/120/120/120/150/151/300/900/200/120/121/120/121/122/123/129/12
Influenza like illnessGeneral disorders3/128/121/64/120/128/120/1210/1211/1210/120/120/120/122/120/127/122/124/122/120/120/120/152/150/300/900/200/120/120/121/122/122/120/122/12
HeadacheNervous system disorders2/121/121/65/120/128/121/128/125/122/121/120/121/120/121/124/122/121/121/122/123/120/152/153/3010/902/201/121/121/120/124/123/121/125/12
FatigueGeneral disorders1/121/121/67/120/126/120/125/121/120/120/120/120/122/121/124/125/121/120/120/120/120/150/150/302/900/200/120/120/120/123/124/122/123/12
Injection site discomfortGeneral disorders0/120/120/61/120/125/120/123/121/121/120/120/120/120/120/120/120/120/120/120/120/120/150/150/300/900/200/120/120/120/122/123/120/120/12
Injection site painGeneral disorders0/120/120/63/120/124/120/123/121/123/120/122/120/120/120/120/120/120/121/120/120/120/150/150/302/902/200/120/120/120/123/122/120/121/12
Periorbital discomfortEye disorders0/120/122/60/120/120/120/120/120/120/120/120/120/120/120/120/120/120/120/120/120/120/150/150/300/900/200/120/120/120/120/120/120/120/12
Decreased appetiteMetabolism and nutrition disorders0/120/120/62/120/120/120/121/123/120/120/121/120/120/120/120/120/120/120/120/120/120/151/150/300/900/201/120/120/120/120/120/120/121/12
PollakiuriaRenal and urinary disorders0/120/120/60/120/120/120/120/120/120/120/120/123/120/120/120/120/120/120/120/120/120/150/150/300/900/200/120/120/120/120/120/120/120/12
PalpitationsCardiac disorders0/120/121/60/120/120/120/120/120/120/120/120/120/120/120/120/120/121/120/120/120/120/150/150/300/900/200/120/120/120/120/120/120/120/12

Baseline characteristics

Age, Continuous
Age, Continuous(years)BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μgBNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μgBNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μgBNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg HIV (Cohort 13)BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg Post-transplant (Cohort 13)BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg (Cohort 11)BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 12)BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 14)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (SD)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (SD)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.6 μg (SD)BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (SD)Total
Mean50.80 ± 2.5848.31 ± 9.0438.22 ± 13.8738.21 ± 10.4841.44 ± 11.2743.62 ± 11.0339.42 ± 11.4135.74 ± 8.6033.88 ± 10.7235.81 ± 12.5064.31 ± 5.8965.66 ± 5.9567.16 ± 6.4736.65 ± 10.1439.64 ± 10.1435.07 ± 10.4642.75 ± 9.8947.21 ± 6.4365.44 ± 7.4265.88 ± 6.5663.87 ± 5.4248.04 ± 10.3648.93 ± 11.8751.92 ± 13.5755.59 ± 16.0748.45 ± 13.8736.42 ± 10.3339.41 ± 12.3434.47 ± 10.2435.42 ± 9.6840.03 ± 14.6735.23 ± 11.8842.40 ± 12.0432.60 ± 10.8747.00 ± 15.34
Sex: Female, Male
Sex: Female, Male(Participants)BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μgBNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μgBNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μgBNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg HIV (Cohort 13)BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg Post-transplant (Cohort 13)BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg (Cohort 11)BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 12)BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 14)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (SD)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (SD)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.6 μg (SD)BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (SD)Total
Female5617684465510857810446839134510853810857261
Male76556488677247542886412617451047942475251
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μgBNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μgBNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μgBNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg HIV (Cohort 13)BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg Post-transplant (Cohort 13)BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg (Cohort 11)BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 12)BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 14)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (SD)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (SD)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.6 μg (SD)BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (SD)Total
Hispanic or Latino00010000010000000000000010002001006
Not Hispanic or Latino1212611121212121211121212121212121212121215153089201212101212111212506
Unknown or Not Reported00000000000000000000000000000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μgBNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μgBNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μgBNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg HIV (Cohort 13)BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg Post-transplant (Cohort 13)BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg (Cohort 11)BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 12)BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 14)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (SD)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (SD)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.6 μg (SD)BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (SD)Total
American Indian or Alaska Native00000000000000000000000000000000000
Asian00000010010000000000010001100001006
Native Hawaiian or Other Pacific Islander00000000000000000000000000000000000
Black or African American00000100000000000000000010000000002
White1212512121111121211121212121212121212121214153089191111121212111212502
More than one race00000000000000000000000000010000001
Unknown or Not Reported00100000000000000000000000000000001
Region of Enrollment
Region of Enrollment(participants)BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μgBNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μgBNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μgBNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg HIV (Cohort 13)BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg Post-transplant (Cohort 13)BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg (Cohort 11)BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 12)BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 14)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (SD)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (SD)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.6 μg (SD)BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (SD)Total
Germany1212612121212121212121212121212121212121215153090201212121212121212512
Weight
Weight(kg)BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μgBNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μgBNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μgBNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg HIV (Cohort 13)BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg Post-transplant (Cohort 13)BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg (Cohort 11)BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 12)BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 14)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (SD)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (SD)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.6 μg (SD)BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (SD)Total
Mean77.68 ± 7.5972.54 ± 10.8578.58 ± 14.9372.99 ± 14.7977.11 ± 14.0771.57 ± 14.0973.58 ± 11.8879.84 ± 13.8176.73 ± 13.3278.70 ± 13.8571.90 ± 10.9870.38 ± 9.1469.98 ± 8.0680.18 ± 14.1377.08 ± 10.8476.11 ± 11.6772.45 ± 10.9777.78 ± 8.4377.87 ± 9.7876.91 ± 12.3875.80 ± 11.9873.85 ± 9.6773.50 ± 10.0777.79 ± 12.9275.44 ± 13.0279.09 ± 14.9467.45 ± 13.5376.41 ± 15.6672.44 ± 6.8670.94 ± 11.4363.75 ± 6.1473.26 ± 15.3973.48 ± 9.5168.90 ± 11.5674.75 ± 12.27
Body mass index
Body mass index(kg/m^2)BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μgBNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μgBNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μgBNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μgBNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μgBNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μgBNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μgBNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg HIV (Cohort 13)BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg Post-transplant (Cohort 13)BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg (Cohort 11)BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 12)BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 14)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg (P/B)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (SD)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (SD)BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.6 μg (SD)BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (SD)Total
Mean24.61 ± 3.1424.23 ± 2.7824.73 ± 2.6325.17 ± 2.8924.94 ± 2.6824.20 ± 2.3224.34 ± 2.3325.68 ± 3.4425.52 ± 3.5025.19 ± 3.0924.73 ± 2.4625.59 ± 2.2225.63 ± 2.2225.25 ± 3.2625.50 ± 2.7925.13 ± 2.0725.43 ± 2.3425.01 ± 1.3825.43 ± 2.1525.62 ± 2.4725.85 ± 2.7523.62 ± 1.9025.63 ± 2.8225.53 ± 2.7225.08 ± 2.7326.12 ± 2.9623.31 ± 2.3825.02 ± 2.8523.83 ± 2.3925.06 ± 3.7322.82 ± 1.5424.97 ± 3.1724.19 ± 2.0424.04 ± 2.5924.98 ± 2.69
09

Study locations

5 sites
  • Contract Research Organization
    Berlin, Germany
  • Universitäts Klinikum
    Frankfurt am Main, Germany
  • Universitäts Klinikum
    Heidelberg, Germany
  • Contract Research Organization
    Kiel, Germany
  • Contract Research Organization
    Mannheim, Germany
10

References and documents

Publications

  • Muik A, Wallisch AK, Sanger B, Swanson KA, Muhl J, Chen W, Cai H, Maurus D, Sarkar R, Tureci O, Dormitzer PR, Sahin U. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. Science. 2021 Mar 12;371(6534):1152-1153. doi: 10.1126/science.abg6105. Epub 2021 Jan 29. PubMed 33514629 ↗
  • Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, Baum A, Pascal K, Quandt J, Maurus D, Brachtendorf S, Lorks V, Sikorski J, Hilker R, Becker D, Eller AK, Grutzner J, Boesler C, Rosenbaum C, Kuhnle MC, Luxemburger U, Kemmer-Bruck A, Langer D, Bexon M, Bolte S, Kariko K, Palanche T, Fischer B, Schultz A, Shi PY, Fontes-Garfias C, Perez JL, Swanson KA, Loschko J, Scully IL, Cutler M, Kalina W, Kyratsous CA, Cooper D, Dormitzer PR, Jansen KU, Tureci O. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2020 Oct;586(7830):594-599. doi: 10.1038/s41586-020-2814-7. Epub 2020 Sep 30. Erratum In: Nature. 2021 Feb;590(7844):E17. doi: 10.1038/s41586-020-03102-w. PubMed 32998157 ↗
  • Sahin U, Muik A, Vogler I, Derhovanessian E, Kranz LM, Vormehr M, Quandt J, Bidmon N, Ulges A, Baum A, Pascal KE, Maurus D, Brachtendorf S, Lorks V, Sikorski J, Koch P, Hilker R, Becker D, Eller AK, Grutzner J, Tonigold M, Boesler C, Rosenbaum C, Heesen L, Kuhnle MC, Poran A, Dong JZ, Luxemburger U, Kemmer-Bruck A, Langer D, Bexon M, Bolte S, Palanche T, Schultz A, Baumann S, Mahiny AJ, Boros G, Reinholz J, Szabo GT, Kariko K, Shi PY, Fontes-Garfias C, Perez JL, Cutler M, Cooper D, Kyratsous CA, Dormitzer PR, Jansen KU, Tureci O. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature. 2021 Jul;595(7868):572-577. doi: 10.1038/s41586-021-03653-6. Epub 2021 May 27. PubMed 34044428 ↗
  • Vogel AB, Kanevsky I, Che Y, Swanson KA, Muik A, Vormehr M, Kranz LM, Walzer KC, Hein S, Guler A, Loschko J, Maddur MS, Ota-Setlik A, Tompkins K, Cole J, Lui BG, Ziegenhals T, Plaschke A, Eisel D, Dany SC, Fesser S, Erbar S, Bates F, Schneider D, Jesionek B, Sanger B, Wallisch AK, Feuchter Y, Junginger H, Krumm SA, Heinen AP, Adams-Quack P, Schlereth J, Schille S, Kroner C, de la Caridad Guimil Garcia R, Hiller T, Fischer L, Sellers RS, Choudhary S, Gonzalez O, Vascotto F, Gutman MR, Fontenot JA, Hall-Ursone S, Brasky K, Griffor MC, Han S, Su AAH, Lees JA, Nedoma NL, Mashalidis EH, Sahasrabudhe PV, Tan CY, Pavliakova D, Singh G, Fontes-Garfias C, Pride M, Scully IL, Ciolino T, Obregon J, Gazi M, Carrion R Jr, Alfson KJ, Kalina WV, Kaushal D, Shi PY, Klamp T, Rosenbaum C, Kuhn AN, Tureci O, Dormitzer PR, Jansen KU, Sahin U. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature. 2021 Apr;592(7853):283-289. doi: 10.1038/s41586-021-03275-y. Epub 2021 Feb 1. PubMed 33524990 ↗
  • Ji RR, Qu Y, Zhu H, Yang Y, Vogel AB, Sahin U, Qin C, Hui A. BNT162b2 Vaccine Encoding the SARS-CoV-2 P2 S Protects Transgenic hACE2 Mice against COVID-19. Vaccines (Basel). 2021 Apr 1;9(4):324. doi: 10.3390/vaccines9040324. PubMed 33915773 ↗
  • Li J, Hui A, Zhang X, Yang Y, Tang R, Ye H, Ji R, Lin M, Zhu Z, Tureci O, Lagkadinou E, Jia S, Pan H, Peng F, Ma Z, Wu Z, Guo X, Shi Y, Muik A, Sahin U, Zhu L, Zhu F. Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study. Nat Med. 2021 Jun;27(6):1062-1070. doi: 10.1038/s41591-021-01330-9. Epub 2021 Apr 22. PubMed 33888900 ↗
  • Muik A, Lui BG, Wallisch AK, Bacher M, Muhl J, Reinholz J, Ozhelvaci O, Beckmann N, Guimil Garcia RC, Poran A, Shpyro S, Finlayson A, Cai H, Yang Q, Swanson KA, Tureci O, Sahin U. Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera. Science. 2022 Feb 11;375(6581):678-680. doi: 10.1126/science.abn7591. Epub 2022 Jan 18. PubMed 35040667 ↗
  • Quandt J, Muik A, Salisch N, Lui BG, Lutz S, Kruger K, Wallisch AK, Adams-Quack P, Bacher M, Finlayson A, Ozhelvaci O, Vogler I, Grikscheit K, Hoehl S, Goetsch U, Ciesek S, Tureci O, Sahin U. Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes. Sci Immunol. 2022 Sep 16;7(75):eabq2427. doi: 10.1126/sciimmunol.abq2427. Epub 2022 Sep 16. PubMed 35653438 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2020 to primary completion in Jun 2021, 14 months.

Results were first posted in Jul 2024, 3 years after primary completion.

Of 80 industry-sponsored phase 1/2 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 14 months is above that.

Counting every sponsor, half of 187 studies reached it within 11 months; a quarter within 4 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2020
First posted
May 8, 2020
StartActual
Apr 23, 2020
Primary completionActual
Jun 30, 2021
CompletionActual
Apr 13, 2022
Results first posted
Jul 12, 2024
Last update
Jul 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT04380701
Lead sponsor
BioNTech SE
Responsible party
Sponsor
First posted
May 8, 2020
Start date
Apr 23, 2020
Primary completion
Jun 30, 2021
Completion
Apr 13, 2022
Results posted
Jul 12, 2024
Last update
Jul 12, 2024

Study contacts

BioNTech Responsible Person
study director · BioNTech SE

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BNT162 Vaccine

Start the discussion